Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Europe Rare Diseases Treatment Market, by Drug Type
1.4.2 Europe Rare Diseases Treatment Market, by Distribution Channel
1.4.3 Europe Rare Diseases Treatment Market, by Route of Administration
1.4.4 Europe Rare Diseases Treatment Market, by Therapeutic Area
1.4.5 Europe Rare Diseases Treatment Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market Composition & Scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. Competition Analysis - Global
3.1 KBV Cardinal Matrix
3.2 Recent Industry Wide Strategic Developments
3.2.1 Partnerships, Collaborations and Agreements
3.2.2 Acquisition and Mergers
3.2.3 Approvals and Trials
3.3 Top Winning Strategies
3.3.1 Key Leading Strategies: Percentage Distribution (2018-2022)
3.3.2 Key Strategic Move: (Acquisitions and Mergers: 2018, Jul – 2022, Aug) Leading Players
Chapter 4. Europe Rare Diseases Treatment Market by Drug Type
4.1 Europe Biologics Market by Country
4.2 Europe Biosimilar Market by Country
4.3 Europe Small Molecule Market by Country
Chapter 5. Europe Rare Diseases Treatment Market by Distribution Channel
5.1 Europe Specialty Pharmacy Market by Country
5.2 Europe Hospital Pharmacy Market by Country
5.3 Europe Online Pharmacy Market by Country
Chapter 6. Europe Rare Diseases Treatment Market by Route of Administration
6.1 Europe Injectable Market by Country
6.2 Europe Oral Market by Country
6.3 Europe Others Market by Country
Chapter 7. Europe Rare Diseases Treatment Market by Therapeutic Area
7.1 Europe Cancer Market by Country
7.2 Europe Cardiovascular Conditions Market by Country
7.3 Europe Infectious Diseases Market by Country
7.4 Europe Musculoskeletal Conditions Market by Country
7.5 Europe Endocrine Disorders Market by Country
7.6 Europe Metabolic Disorders Market by Country
7.7 Europe Hematologic Disorders Market by Country
7.8 Europe Neurological Conditions Market by Country
7.9 Europe Others Market by Country
Chapter 8. Europe Rare Diseases Treatment Market by Country
8.1 Germany Rare Diseases Treatment Market
8.1.1 Germany Rare Diseases Treatment Market by Drug Type
8.1.2 Germany Rare Diseases Treatment Market by Distribution Channel
8.1.3 Germany Rare Diseases Treatment Market by Route of Administration
8.1.4 Germany Rare Diseases Treatment Market by Therapeutic Area
8.2 UK Rare Diseases Treatment Market
8.2.1 UK Rare Diseases Treatment Market by Drug Type
8.2.2 UK Rare Diseases Treatment Market by Distribution Channel
8.2.3 UK Rare Diseases Treatment Market by Route of Administration
8.2.4 UK Rare Diseases Treatment Market by Therapeutic Area
8.3 France Rare Diseases Treatment Market
8.3.1 France Rare Diseases Treatment Market by Drug Type
8.3.2 France Rare Diseases Treatment Market by Distribution Channel
8.3.3 France Rare Diseases Treatment Market by Route of Administration
8.3.4 France Rare Diseases Treatment Market by Therapeutic Area
8.4 Russia Rare Diseases Treatment Market
8.4.1 Russia Rare Diseases Treatment Market by Drug Type
8.4.2 Russia Rare Diseases Treatment Market by Distribution Channel
8.4.3 Russia Rare Diseases Treatment Market by Route of Administration
8.4.4 Russia Rare Diseases Treatment Market by Therapeutic Area
8.5 Spain Rare Diseases Treatment Market
8.5.1 Spain Rare Diseases Treatment Market by Drug Type
8.5.2 Spain Rare Diseases Treatment Market by Distribution Channel
8.5.3 Spain Rare Diseases Treatment Market by Route of Administration
8.5.4 Spain Rare Diseases Treatment Market by Therapeutic Area
8.6 Italy Rare Diseases Treatment Market
8.6.1 Italy Rare Diseases Treatment Market by Drug Type
8.6.2 Italy Rare Diseases Treatment Market by Distribution Channel
8.6.3 Italy Rare Diseases Treatment Market by Route of Administration
8.6.4 Italy Rare Diseases Treatment Market by Therapeutic Area
8.7 Rest of Europe Rare Diseases Treatment Market
8.7.1 Rest of Europe Rare Diseases Treatment Market by Drug Type
8.7.2 Rest of Europe Rare Diseases Treatment Market by Distribution Channel
8.7.3 Rest of Europe Rare Diseases Treatment Market by Route of Administration
8.7.4 Rest of Europe Rare Diseases Treatment Market by Therapeutic Area
Chapter 9. Company Profiles
9.1 AbbVie, Inc.
9.1.1 Company Overview
9.1.2 Financial Analysis
9.1.3 Regional Analysis
9.1.4 Research & Development Expense
9.1.5 Recent strategies and developments:
9.1.5.1 Partnerships, Collaborations, and Agreements:
9.2 F. Hoffmann-La Roche Ltd.
9.2.1 Company Overview
9.2.2 Financial Analysis
9.2.3 Segmental and Regional Analysis
9.2.4 Research & Development Expense
9.2.5 Recent strategies and developments:
9.2.5.1 Acquisition and Mergers:
9.3 Bayer AG
9.3.1 Company Overview
9.3.2 Financial Analysis
9.3.3 Segmental and Regional Analysis
9.3.4 Research & Development Expense
9.4 Novartis AG
9.4.1 Company Overview
9.4.2 Financial Analysis
9.4.3 Segmental and Regional Analysis
9.4.4 Research & Development Expense
9.4.5 Recent strategies and developments:
9.4.5.1 Approval and Trails:
9.5 Merck Group
9.5.1 Company Overview
9.5.2 Financial Analysis
9.5.3 Segmental and Regional Analysis
9.5.4 Research & Development Expense
9.5.5 Recent strategies and developments:
9.5.5.1 Acquisition and Mergers:
9.6 Bristol Myers Squibb Company
9.6.1 Company Overview
9.6.2 Financial Analysis
9.6.3 Regional Analysis
9.6.4 Research & Development Expenses
9.6.5 Recent strategies and developments:
9.6.5.1 Acquisition and Mergers:
9.7 Pfizer, Inc.
9.7.1 Company Overview
9.7.2 Financial Analysis
9.7.3 Regional & Segmental Analysis
9.7.4 Research & Development Expense
9.7.5 Recent strategies and developments:
9.7.5.1 Partnerships, Collaborations, and Agreements:
9.7.5.2 Acquisitions and Mergers:
9.8 AstraZeneca PLC
9.8.1 Company Overview
9.8.2 Financial Analysis
9.8.3 Regional Analysis
9.8.4 Research & Development Expenses
9.8.5 Recent strategies and developments:
9.8.5.1 Partnerships, Collaborations, and Agreements:
9.8.5.2 Acquisition and Mergers:
9.8.5.2 Takeda Pharmaceutical Company Limited
9.9.1 Company Overview
9.9.2 Financial Analysis
9.9.3 Regional Analysis
9.9.4 Research & Development Expense
9.9.5 Recent strategies and developments:
9.9.5.1 Partnerships, Collaborations, and Agreements:
9.9.5.2 Acquisition and Mergers:
9.10. PTC Therapeutics, Inc.
9.10.1 Company Overview
9.10.2 Financial Analysis
9.10.3 Regional Analysis
9.10.4 Research & Development Expenses
9.10.5 Recent strategies and developments:
9.10.5.1 Partnerships, Collaborations, and Agreements:
9.10.5.2 Acquisition and Mergers:
Unique Offerings 
